Evident Vascular's Guidance System and Imaging Catheeters Receive FDA Clearance

November 10, 2026—Evident Vascular, Inc. announced FDA 510(k) clearance of the Evident Vascular guidance system and Evident peripheral imaging catheters. The guidance system is intended for ultrasound examination of intravascular pathology during peripheral vascular interventions.

According to the company, the intravascular ultrasound imaging platform brings together high-fidelity imaging, purpose-built artificial intelligence (AI), and workflow without disruption. 

Evident stated its high-fidelity imaging integrates broad frequency bandwidth, advanced transducer design, and advanced signal processing. Additionally, the company’s DFC technology provides dynamic frequency control to optimize imaging.

Eric A. Secemsky, MD, Director of Vascular Intervention at Beth Israel Deaconess Medical Center in Boston, Massachusetts, discussed the Evident technology in the company’s press release.

“The vessel-edge clarity and consistency across the field of view are remarkable,” commented Dr. Secemsky. “By optimizing resolution and penetration across a range of vessel sizes and imaging depths, Evident’s technology provides detailed images for physicians to consider when measuring vessels, making decisions about therapy, and assessing procedural results.”

The company further stated that the Evident platform pairs custom imaging electronics with real-time image processing on NVIDIA accelerated computing. Evident Vascular is a member of the NVIDIA Inception program for startups. Evident’s AI workstation and stack of advanced software are designed to enable AI directly at the point of care. As clinical experience and data grow, the company intends to expand the platform’s AI capabilities, introducing new features designed to further enhance imaging, workflow, and the overall user experience, noted the press release.